HBV and HCV therapy

Viruses

Volumn 1, Issue 3, 2009, Pages 484-509

  Lampertico, Pietro ^a   Aghemo, Alessio ^a   Viganò, Mauro ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

HBV DNA; HCV RNA; Nucleos(t)ide analogues; Peg IFN; Resistance; Ribavirin; SVR

Indexed keywords

EID: 84893499025     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v1030484     Document Type: Review

References (122)

1. Lok, A.S.; McMahon, B.J. Chronic hepatitis B. Hepatology 2007, 45, 507-539.
2. Liaw, Y.F.; Leung, N.; Guan, R.; Lau, G.K.; Merican, I.; McCaughan, G.; Gane, E.; Kao, J.H.; Omata, M.; Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005, 25, 472-489.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J. Hepatol. 2009, 50, 227-242.
4. Fattovich, G. Natural history and prognosis of hepatitis B. Semin. Liver Dis. 2003, 23, 47-58.
5. Fattovich, G.; Bortolotti, F.; Donato, F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 2008, 48, 335-352.
6. McMahon, B.J. The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. 2004, 24, 17-21.
7. Hsu, Y. S; Chien, R.N.; Yeh, C.T.; Sheen, I.S.; Chiou, H.Y.; Chu, C.M.; Liaw, Y.F. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35, 1522-1527.
8. van Zonneveld M.; Honkoop P.; Hansen B.E.; Niesters H.G.; Darwish Murad S.; de Man R.A.; Schalm S.W.; Janssen H.L. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004, 39, 804-810.
9. Niederau, C.; Heintges, T.; Lange, S.; Goldmann, G.; Niederau, C.M.; Mohr, L.; Häussinger, D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 1996, 334, 1422-1427.
10. Papatheodoridis, G.V.; Manesis, E.; Hadziyannis, S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. 2001, 34, 306-313.
11. Brunetto, M.R.; Oliveri, F.; Coco, B.; Leandro, G.; Colombatto, P.; Gorin, J.M.; Bonino, F. Outcome of anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J. Hepatol. 2002, 36, 263-270.
12. Lampertico, P.; Del Ninno, E.; Viganò, M.; Romeo, R.; Donato, M.F.; Sablon, E.; Morabito, A.; Colombo M. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37, 756-763.
13. Di Marco, V.; Lo Iacono, O.; Cammà, C.; Vaccaro, A.; Giunta, M.; Martorana, G.; Fuschi, P.; Almasio, P.L.; Craxì, A. The long term course of chronic hepatitis B. Hepatology 1999, 30, 257-264.
14. Bonino, F.; Brunetto, M.R. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J. Hepatol. 2003, 39, S160-S163.
15. Hadziyannis, S.J.; Papatheodoridis, G.V. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin. Liver Dis. 2006, 26, 130-141.
16. Di Marco, V.; Marzano, A.; Lampertico, P.; Andreone, P.; Santantonio, T.; Almasio, P.L.; Rizzetto, M.; Craxì, A.; Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004, 40, 883-891.
17. Wong, D.K.; Cheung, A.M.; O'Rourke, K.; Naylor, C.D.; Detsky, A.S.; Heathcote, J. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann. Intern. Med. 1993, 119, 312-323.
18. Lau, G.K.; Piratvisuth, T.; Luo, K.X.; Marcellin, P.; Thongsawat, S.; Cooksley, G.; Gane, E.; Fried, M.W.; Chow, W.C.; Paik, S.W.; Chang, W.Y.; Berg, T.; Flisiak, R.; McCloud, P.; Pluck, N.; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005, 352, 2682-2695.
19. Janssen, H.L.; van Zonneveld, M.; Senturk, H.; Zeuzem, S.; Akarca, U.S.; Cakaloglu, Y.; Simon, C.; So T.M.; Gerken, G.; de Man, R.A.; Niesters, H.G.; Zondervan, P.; Hansen, B.; Schalm, S.W.; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365, 123-129.
20. Buster, E.H.; Flink, H.J.; Cakaloglu, Y.; Simon, K.; Trojan, J.; Tabak, F.; So, T.M.; Feinman, S.V.; Mach, T.; Akarca, U.S.; Schutten, M.; Tielemans, W.; van Vuuren, A.J.; Hansen, B.E.; Janssen, H.L. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135, 459-467.
21. Fried, M.W.; Piratvisuth, T.; Lau, G.K.K.; Marcellin, P.; Chow, W.C.; Cooksley, G.; Luo, K.X.; Paik, S.W.; Liaw, Y.F.; Button, P.; Popescu, M. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47, 428-434.
22. Wai, C.T.; Chu, C.J.; Hussain, M.; Lok, A.S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002, 36, 1425-1430.
23. Flink, H.J.; van Zonneveld, M.; Hansen, B.E.; de Man, R.A.; Schalm, S.W.; Janssen, H.L. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol. 2006, 101, 297-303.
24. Lai, C.L.; Chien, R.N.; Leung, N.W.; Chang, T.T.; Guan, R.; Tai, D.I.; Ng, K.Y.; Wu, P.C.; Dent, J.C.; Barber, J.; Stephenson, S.L.; Gray, D.F. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998, 339, 61-68.
25. Dienstag, J.L.; Schiff, E.R.; Wright, T.L.; Perrillo, R.P.; Hann, H.W.; Goodman, Z.; Crowther, L.; Condreay, L.D.; Woessner, M.; Rubin, M.; Brown, N.A. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999, 341, 1256-1263.
26. Marcellin, P.; Chang, T.T.; Lim, S.G.; Tong, M.J.; Sievert, W.; Shiffman, M.L.; Jeffers, L.; Goodman, Z.; Wulfsohn, M.S.; Xiong, S.; Fry, J.; Brosgart, C.L.; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003, 348, 808-816.
27. Chang, T.T.; Gish, R.G.; de Man, R.; Gadano, A.; Sollano, J.; Chao, Y.C.; Lok, A.S.; Han, K.H.; Goodman, Z.; Zhu, J.; Cross, A.; DeHertogh, D.; Wilber, R.; Colonno, R.; Apelian, D.; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006, 354, 1001-1010.
28. Lai, C.L.; Gane, E.; Liaw, Y.F.; Hsu, CW, Thongsawat, S.; Wang, Y.; Chen, Y.; Heathcote, E.J.; Rasenack, J.; Bzowej, N.; Naoumov, N.V.; Di Bisceglie, A.M.; Zeuzem, S.; Moon, Y.M.; Goodman, Z.; Chao, G.; Constance, B.F.; Brown, N.A.; Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007, 357, 2576-2588.
29. Marcellin, P.; Heathcote, E.J.; Buti, M.; Gane, E.; de Man, R.A.; Krastev, Z.; Germanidis, G.; Lee, S.S.; Flisiak, R.; Kaita, K.; Manns, M.; Kotzev, I.; Tchernev, K.; Buggisch, P.; Weilert, F.; Kurdas, O.O.; Shiffman, M.L.; Trinh, H.; Washington, M.K.; Sorbel, J.; Anderson, J.; Snow-Lampart, A.; Mondou, E.; Quinn, J.; Rousseau, F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008, 359, 2442-2455.
30. Chang, T.T.; Lai, C.L.; Chien, R.N.; Guan, R.; Lim, S.G.; Lee, C.M.; Ng, K.Y.; Nicholls, G.J.; Dent, J.C.; Leung, N.W. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2004, 19, 1276-1282.
31. Leung, N.W.; Lai, C.L.; Chang, T.T.; Guan, R.; Lee, C.M.; Ng, K.Y.; Lim, S.G.; Wu, P.C.; Dent, J.C.; Edmundson, S.; Condreay, L.D.; Chien, R.N.; Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33, 1527-1532.
32. Sheldon, J.; Rodès, B.; Zoulim, F.; Bartholomeusz, A.; Soriano, V. Mutations affecting the replication capacity of the hepatitis B virus. J. Viral. Hep. 2006, 13, 427-434.
33. Doo, E.; Liang, J.T. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001, 120, 1000-1008.
34. Brunelle, M.N.; Jacquard, A.C.; Pichoud, C.; Durantel, D.; Carrouée-Durantel, S.; Villeneuve, J.P.; Trépo, C.; Zoulim, F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41, 1391-1398.
35. Zoulim, F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res. 2004, 64, 1-15.
36. Locarnini, S.; Hatzakis, A.; Heathcote, J.; Keeffe, E.B.; Liang, T.J.; Mutimer, D.; Pawlotsky, J.M.; Zoulim, F. Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Ther. 2004, 9, 679-693.
37. Keeffe, E.; Dieterich, D.T.; Han, S.H.B.; Jacobson, I.M.; Martin, P.; Schiff, E.R.; Tobias, H.; Wright, T.L. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin. Gastroenterol. Hepatol. 2006, 2, 87-106.
38. Yuen, M.F.; Sablon, E.; Hui, C.K.; Yuan, H.J.; Decraemer, H.; Lai, C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34, 785-791.
39. Yuen, M.F.; Fong, D.Y.; Wong, D.K.; Yuen, J.C.; Fung, J.; Lai, C.L. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007, 46, 1695-1703.
40. Dienstag, J.L.; Cianciara, J.; Karayalcin, S.; Kowdley, K.V.; Willems, B.; Plisek, S.; Woessner, M.; Gardner, S.; Schiff, E. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003, 37, 748-755.
41. Song, B.C.; Suh, D.J.; Lee, H.C.; Chung, Y.H.; Lee, Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000, 32, 803-806.
42. Lee, K.M.; Cho, S.W.; Kim, S.W.; Kim, H.J.; Hahm, K.B.; Kim, J.H. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J. Viral. Hep. 2002, 9, 208-212.
43. Liaw, Y.F.; Sung, J.J.; Chow, W.C.; Farrell, G.; Lee, C.Z.; Yuen, H.; Tanwandee, T.; Tao, Q.M.; Shue, K.; Keene, O.N.; Dixon, J.S.; Gray, D.F.; Sabbat, J.; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004, 351, 1521-1531.
44. Marcellin, P.; Chang, T.T.; Lim, S.G.; Sievert, W.; Tong, M.; Arterburn, S.; Borroto-Esoda, K.; Frederick, D.; Rousseau, F. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48, 750-758.
45. Gish, R.G.; Lok, A.S.; Chang, T.T.; De Man, R.A.; Gadano, A.; Sollano, J.; Han, H.H.; Chao, Y.C.; Lee, S.-D.; Harris, M.; Yang, J.; Colonno, R.; Brett-Smith, H. Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. Gastroenterology 2007, 133, 1437-1444
46. Colonno, R.J.; Rose, R.E.; Baldick, C.J.; Levine, S.M.; Klesczewski, K.; Tenney, D.J. High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy. J. Hepatol. 2006, 44 (Suppl. 2), 182.
47. Tenney, D.J.; Rose, R.E.; Baldick, C.J.; Pokornowski, K.A.; Eggers, B.J.; Fang, J.; Wichroski, M.J.; Xu, D.; Yang, J.; Wilber, R.B.; Colonno, R.J. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009, 49, 1503-1514.
48. Heathcote, E.; Gane, E.J.; deMan, R.A.; Chan, S.; Sievert, W.; Mauss, S.; Marcellin, P.; Sorbel, J.; Anderson, J.; Mondou, E.; Quinn, J.; Rousseau, F. Two year tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis. Hepatology 2008, 48 (Supp. 1), 376A.
49. Zoulim, F.; Perrillo, R. Hepatitis B: reflections on the current approach to antiviral therapy. J. Hepatol. 2008, 48 (Suppl. 1), 2-19.
50. Manesis, E.K.; Hadziyannis, S.J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001, 121, 101-109.
51. Marcellin, P.; Lau, G.K.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.M.; Piratvisuth, T.; Germanidis, G.; Yurdaydin, C.; Diago, M.; Gurel, S.; Lai, M.Y.; Button, P.; Pluck, N.; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004, 351, 1206-1217.
52. Bonino, F.; Marcellin, P.; Lau, G.K.; Hadziyannis, S.; Jin, R.; Piratvisuth, T.; Germanidis, G.; Yurdaydin, C.; Diago, M.; Gurel, S.; Lai, M.Y.; Brunetto, M.R.; Farci, P.; Popescu, M.; McCloud, P.; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007, 56, 699-705.
53. Marcellin, P.; Bonino, F.; Lau, G.K.; Farci, P.; Yurdaydin, C.; Piratvisuth, T.; Luo, K.; Gurel, S.; Hadziyannis, S.; Wang, Y.; Popescu, M.; Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (40KD) + lamivudine: 3-year follow-up results. J. Hepatol. 2007, 46 (Suppl. 1), 25-26.
54. Hadziyannis, S.J.; Papatheodoridis, G.V.; Dimou, E.; Laras, A.; Papaioannou, C. Efficacy of longterm lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000, 32, 847-851.
55. Tassopoulos, N.C.; Volpes, R.; Pastore, G.; Heathcote, J.; Buti, M.; Goldin, R.D.; Hawley, S.; Barber, J.; Condreay, L.; Gray, D.F. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. J. Hepatol. 1999, 30 (Suppl. 1), 117.
56. Santantonio, T.; Mazzola, M.; Iacovazzi, T.; Miglietta, A.; Guastadisegni, A.; Pastore, G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 2000, 32, 300-306.
57. Hadziyannis, S.J.; Tassopoulos, N.C.; Heathcote, E.J.; Chang, T.T.; Kitis, G.; Rizzetto, M.; Marcellin, P.; Lim, S.G.; Goodman, Z.; Wulfsohn, M.S.; Xiong, S.; Fry, J.; Brosgart, C.L.; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B antigennegative chronic hepatitis B. N. Engl. J. Med. 2003, 348, 800-807.
58. Hadziyannis, S.J.; Tassopoulos, N.C.; Heathcote, E.J.; Chang, T.T.; Kitis, G.; Rizzetto, M.; Marcellin, P.; Lim, S.G.; Goodman, Z.; Ma, J.; Brosgart, C.L.; Borroto-Esoda, K.; Arterburn, S.; Chuck, S.L.; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131, 1743-1751.
59. Hadziyannis, S.; Sevastianos, V.; Rapti, I.N.; Tassopoulos, N. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology 2006, 44, 231A.
60. Lai, C.L.; Shouval, D.; Lok, A.S.; Chang, T.T.; Cheinquer, H.; Goodman, Z.; DeHertogh, D.; Wilber, R.; Zink, R.C.; Cross, A.; Colonno, R.; Fernandes, L.; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006, 354, 1011-1020.
61. Shouval, D.; Akarca, U.S.; Hatzis, G.; Kitis, G.; Lai, C.L.; Cheinquer, H.; Chang, T.T.; Zinc, R.; Zhu, J.; Brett-Smith, H. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). J. Hepatol. 2006, 44, S21.
62. Lai, C.L.; Gane, E.; Hsu, C.W.; Thongsawat, S.; Wang, Y.; Chen, Y.; Heathcote, E.J.; Rasenack, J.; Bzowej, N.; Naoumov, N.; Zeuzem, S.; Di Bisceglie, A.; Chao, G.C.; Fielman, B.A.; Brown, N.A.; Study Group Globe. Two-year results from the Globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for Telbivudine (LdT) vs. Lamivudine. Hepatology 2006, 44, 222A.
63. Di Bisceglie, A.; Lai, C.L.; Gane, E.; Chen, Y.; Thongsawat, S.; Wang, Y.; Heathcote, E.J.; Zeuzem, S.; Rasenack, J.; Bzowej, N.; Han, S.H.; Naoumov, N.; Hwang, S.G.; Lim, S.G.; Chao, G.C.; Fielman, B.A.; Brown, N.A.; Study Group Globe The GLOBE16; 1St Telbivudine Globe trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleosidetreated hepatitis B patients. Hepatology 2006, 44, 230A.
64. Marcellin, P.; Buti, M.; Krastev, M.; Gurel, S.; Balabanska, R.I.; Dusheiko, G.; Myers, R.P.; Heathcote, E.J.; Sorbel, J.; Anderson, E.; Mondou, E.; Rousseau, F. Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102), Preliminary Analysis. Hepatology 2008, 48, 370A
65. Zoulim, F. Combination of nucleoside analogues in the treatment of chronic hepatitis B infection: lesson from experimental models. J. Antimic. Chemoter. 2005, 55, 608-611.
66. Westland, C.E.; Yang, H.; Delaney, W.E. 4th; Wulfsohn, M.; Lama, N.; Gibbs, C.S.; Miller, M.D.; Fry, J.; Brosgart, C.L.; Schiff, E.R.; Xiong, S. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J. Viral Hepat. 2005, 12, 67-73.
67. Angus, P.; Vaughan, R.; Xiong, S.; Yang, H.; Delaney, W.; Gibbs, C.; Brosgart, C.; Colledge, D.; Edwards, R.; Ayres, A.; Bartholomeusz, A.; Locarnini, S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125, 292-297.
68. Villeneuve, J.P.; Durantel, D.; Durantel, S.; Westland, C.; Xiong, S.; Brosgart, C.L.; Gibbs, C.S.; Parvaz, P.; Werle, B.; Trépo, C.; Zoulim, F. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 2003, 39, 1085-1089.
69. Lampertico, P.; Viganò, M.; Manenti, E.; Iavarone, M.; Sablon, E.; Colombo, M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007, 133, 1445-1451.
70. Nguyen, M.H.; Keeffe, E.B. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J. Viral Hepat. 2009, 16, 149-55.
71. Rapti, I.; Dimou, E.; Mitsoula, P.; Hadziyannis, S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007, 45, 307-313.
72. Lampertico, P.; Marzano, A.; Levrero, M.; Santantonio, T.; Di Marco, V.; Brunetto M.; Andreone P.; Sagnelli, E.; Fagiuoli, S.; Mazzella, G.; Raimondo, G.; Gaeta, G.; Ascione, A. on behalf of the Italian Association for the Study of the Liver (AISF). Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAgnegative chronic hepatitis B. J. Hepatol. 2007, 46, S191.
73. Lampertico, P.; Viganò, M.; Manenti, E.; Iavarone, M.; Lunghi, G.; Colombo, M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005, 42, 1414-1419.
74. Benhamou, Y.; Thibault, V.; Vig, P.; Calvez, V.; Marcelin, A.G.; Fievet, M.H.; Currie, G.; Chang, C.G.; Biao, L.; Xiong, S.; Brosgart, C.; Poynard, T. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J. Hepatol. 2006, 44, 62-67.
75. Yatsuji, H.; Suzuki, F.; Sezaki, H.; Akuta, N.; Suzuki, Y.; Kawamura, Y.; Hosaka, T.; Kobayashi, M.; Saitoh, S.; Arase, Y.; Ikeda, K.; Watahiki, S.; Iwasaki, S.; Kobayashi, M.; Kumada, H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J. Hepatol. 2008, 48, 923-931.
76. Lampertico, P.; Viganò, M.; Facchetti, F.; Iavarone, M.; Colombo, M. Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B: low risk of genotypic resistance to ADV and prevention of virologic breakthrough. Hepatology 2008, 48, 712A
77. Hadziyannis, S.J.; Costamena, A.; Laras, A.; Hadziyannis, E. Predictors/determinants of sustained virological response (SVR) and of HBsAg loss following long term adefovir dipivoxil (ADV) therapy in HBeAg-negative chronic hepatitis B (CHB). Hepatology 2008, 48, 896A.
78. Villet, S.; Pichoud, C.; Villeneuve, J.P.; Trépo, C.; Zoulim, F. Selection of a multiple drugresistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006, 131, 1253-1261.
79. Keeffe, E.B.; Zeuzem, S.; Koff, R.S.; Dieterich, D.T.; Esteban-Mur, R.; Gane, E.J.; Jacobson, I.M.; Lim, S.G.; Naoumov, N.; Marcellin, P.; Piratvisuth, T.; Zoulim, F. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2007, 5, 890-897.
80. Armstrong, G.L.; Wasley, A.; Simard, E.P.; McQuillan, G.M.; Kuhnert, W.L.; Alter, M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 2006, 144, 705-714.
81. Esteban, J.I.; Sauleda, S.; Quer, J. The changing epidemiology of hepatitis C virus infection in Europe. J. Hepatol. 2008, 48, 148-162.
82. Bosetti, C.; Levi, F.; Lucchini, F.; Zatonski, W.A.; Negri, E.; La Vecchia, C. Worldwide mortality from cirrhosis: an update to 2002. J. Hepatol. 2007, 46, 827-839.
83. Sangiovanni, A.; Prati, G.M.; Fasani, P.; Ronchi, G.; Romeo, R.; Manini, M.; Del Ninno, E.; Morabito, A.; Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006, 43, 1303-1310.
84. Hoofnagle, J.H.; Mullen, K.D.; Jones, D.B.; Rustgi, V.; Di Bisceglie, A.; Peters, M.; Waggoner, J.G.; Park, Y.; Jones, E.A. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 1986, 315, 1575-1578.
85. Poynard, T.; Marcellin, P.; Lee, S.S.; Niederau, C.; Minuk, G.S.; Ideo, G.; Bain, V.; Heathcote, J.; Zeuzem, S.; Trepo, C.; Albrecht, J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352, 1426-1432.
86. McHutchison, J.G.; Gordon, S.C.; Schiff, E.R.; Shiffman, M.L.; Lee, W.M.; Rustgi, V.K.; Goodman, Z.D.; Ling, M.H.; Cort, S.; Albrecht, J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998, 339, 1485-1492.
87. Feld, J.J.; Hoofnagle, J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436, 967-972.
88. Harris, J.M.; Martin, N.E.; Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 2001, 40, 539-551.
89. Glue, P.; Fang, J.W.; Rouzier-Panis, R.; Raffanel, C.; Sabo, R.; Gupta, S.K.; Salfi, M.; Jacobs, S. Pegylated interferon-alpha-2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin. Pharmacol. Ther. 2000, 68, 556-567.
90. Bailon, P.; Palleroni, A.; Schaffer, C.A.; Spence, C.L.; Fung, W.J.; Porter, J.E.; Ehrlich, G.K.; Pan, W.; Xu, Z.X.; Modi, M.W.; Farid, A.; Berthold, W.; Graves, M. Rational design of a potent, long-lasting form of interferon: a 40 KDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 2001, 12, 195-202.
91. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.; Albrecht, J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358, 958-965.
92. Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.; Marinos, G.; Goncales, F.L.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975-982.
93. Caliceti, P. Pharmacokinetics of pegylated interferons: what is misleading? Dig. Liver Dis. 2004, 36 (Suppl. 3), 334-339.
94. Bruno, R.; Sacchi, P.; Ciappina, V.; Zocchetti, C.; Patruno, S.; Maiocchi, L.; Filice, G. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naïve patients with chronic hepatitis C: a randomized, controlled study. Antivir. Ther. 2004, 9, 491-497.
95. Silva, M.; Poo, J.; Wagner, F.; Jackson, M.; Cutler, D.; Grace, M.; Bordens, R.; Cullen, C.; Harvey, J.; Laughlin, M. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J. Hepatol. 2006, 45, 204-213.
96. Di Bisceglie, A.M.; Ghalib, R.H.; Hamzeh, F.; Rustgi, V.K. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J. Viral Hep. 2007, 14, 721-729.
97. Rumi, M.G.; Aghemo, A.; Prati, G.M.; D'Ambrosio, R.; Donato, M.F.; Russo, A.; Cerami, N.; Soffredini, R.; Colombo M. Randomized study comparing peginterferon-alfa2a plus ribavirin and peginterferon-alfa2b plus ribavirin in naïve patients with chronic hepatitis C: final results of the Milan safety tolerability (MIST) study. Hepatology 2008, 48 (Suppl.) 404A.
98. Ascione, A.; De Luca, M.; Tartaglione, M.T.; Lampasi, F.; Galeota Lanza, A.; Picciotto, F.P.; Di Costanzo, G.G.; Leandro, G. Peginterferon alpha-2a plus ribavirin versus Peginterferon alpha-2b plus ribavirin in naïve patients with chronic hepatitis C virus infection: results of a prospective randomised trial. J. Hepatol. 2008, 48 (Suppl. 2), 370.
99. Sulkowski, E.; Lawitz, M.L.; Shiffman, M.L.; Muir, A.J.; Galler, G.; McCone, J.; Nyberg, L.; Lee, W.M.; Ghalib, R.; Schiff, E.; Galati, J.; Bacon, B.; Davis, M.; Mukhopadhyay, P.; NOviello, S.; Pedicone, L.; Albrecht, J.; McHutchison, J. Final results of the ideal (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIB study. J. Hepatol. 2008, 48 (Suppl. 2), 370.
100. Jacobson, I.M.; Brown, R.S.; Freilich, B.; Afdhal, N.; Kwo, P.J.; Santoro, J.; Becker, S.; Wakil, A.E.; Pound, D.; Godofsky, E.; Strauss, R.; Bernstein, D.; Flamm, S.; Pauly, M.P.; Mukhopadhyay, P.; Griffel, L.H.; Brass, C.A.; WIN-R Study Group. Peginterferon alfa-2b and weight-based of flat-dose ribavirin in Chronic hepatitis C Patients: a randomized trial. Hepatology 2007, 46, 971-981.
101. Zeuzem, S.; Hultcrantz, R.; Bourliere, M.; Goeser, T.; Marcellin, P.; Sanchez-Tapias, J.; Sarrazin, C.; Harvey, J.; Brass, C.; Albrecht, J. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 2004, 40, 993-999.
102. Davis, G.L.; Wong, J.B.; McHutchison, J.G.; Manns, M.P.; Harvey, J.; Albrecht, J. Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38, 645-652.
103. Ghany, M.G.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49, 1335-1374.
104. Ferenci, P.; Fried, M.W.; Shiffman, M.L.; Smith, C.I.; Marinos, G.; Goncales, F.R. Jr.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxì, A.; Chaneac, M.; Reddy, K.R. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol. 2005, 43, 425-433.
105. Dalgard, O.; Bjøro, K.; Hellum, K.B.; Myrvang, B.; Ritland, S.; Skaug, K.; Raknerud, N.; Bell, H. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004, 40, 1260-1265
106. Zeuzem, S.; Buti, M.; Ferenci, P.; Sperl, J.; Horsmans, Y.; Cianciara, J.; Ibranyi, E.; Weiland, O.; Noviello, S.; Brass, C.; Albrecht, J. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 2006, 44, 97-103.
107. Jensen, D.M.; Morgan, T.R.; Marcellin, P.; Pockros, P.J.; Reddy, K.R.; Hadziyannis, S.J.; Ferenci, P.; Ackrill, A.M.; Willems, B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43, 954-960.
108. Mangia, A.; Santoro, R.; Minerva, N.; Ricci, G.L.; Carretta, V.; Persico, M.; Vinelli, F.; Scotto, G.; Bacca, D.; Annese, M.; Romano, M.; Zechini, F.; Sogari, F.; Spirito, F.; Andriulli, A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 2005, 352, 2609-2617.
109. von Wagner, M.; Huber, M.; Berg, T.; Hinrichsen, H.; Rasenack, J.; Heintges, T.; Bergk, A.; Bernsmeier, C.; Haussinger, D.; Herrmann, E.; Zeuzem, S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129, 522-527.
110. Shiffman, M.L.; Suter, F.; Bacon, B.R.; Nelson, D.; Harley, H.; Solà, R.; Shafran, S.D.; Barange, K.; Lin, A.; Soman, A.; Zeuzem, S.; ACCELLERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 2007, 357, 124-134.
111. Lagging, M.; Langeland, N.; Pedersen, C.; Färkillä, M.; Buhl, M.R.; Mørch, K.; Dhillon, A.P.; Alsiø, A.; Hellstrand, K.; Westin, J.; Norkrans, G.; NORDynamiC Study Group. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008, 47, 1837-1845.
112. Dalgard, O.; Bjøro, K.; Ring-Larsen, H.; Bjornsson, E.; Holberg-Petersen, M.; Skovlund, E.; Reichard, O.; Myrvang, B.; Sundeløf, B.; Ritland, S.; Hellum, K.; Fridén, A.; Florholmen, J.; Verbaan, H.; North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008, 47, 35-42.
113. Mangia, A.; Minerva, N.; Bacca, D.; Cozzolongo, R.; Agostinacchio, E.; Sogari, F.; Scotto, G.; Vinelli, F.; Ricci, G.L.; Romano, M.; Carretta, V.; Petruzzellis, D.; Andriulli, A. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009, 49, 358-363.
114. Berg, T.; von Wagner, M.; Nasser, S.; Sarrazin, C.; Heintges, T.; Gerlac, T.; Buggisch, P.; Goeser, T.; Rasenack, J.; Pape, G.R.; Schmidt, W.E.; Kallinowski, B.; Klinker, H.; Spengler, U.; Martus, P.; Aishuth, U.; Zeuzem, S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130, 1086-1097.
115. Pearlman, B.L.; Ehleben, C.; Saifee, S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007, 46, 1688-1694.
116. Buti, M.; Lurie, Y.; Zakharova, N.G.; Blokhina, N.P.; Horban, A.; Sarrazin, C.; Balciuniene, L.; Chen, R.; Yu, X.; Faruqi, R.; Esteban, R. Extended treatment duration in chronic hepatitis C genotype 1-infected slow responders: final results of the SUCCESS study. J. Hepatol. 2009, 50 (Suppl. 1), 58.
117. McHutchison, J.G.; Bartenschlager, R.; Patel, K.; Pawlotsky, J.M. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J. Hepatol. 2006, 44, 411-421.
118. Shiffman, M.L.; Di Bisceglie, A.M.; Lindsay, K.L.; Norishima, C.; Wright, E.C.; Everson, G.T.; Lok, A.S.; Morgan, T.R.; Bonkovsky, H.L.; Lee, W.M.; Dienstag, J.L.; Ghany, M.G.; Goodman, Z.D.; Everhart, J.E. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126, 1015-1023.
119. Poynard, T.; Colombo, M.; Bruix, J.; Schiff, E.; Terg, R.; Flamm, S.; Moreno-Otero, R.; Carrilho, F.; Schmidt, W.; Berg, T.; McGarrity, T.; Heathcote, E.J.; Goncales, F.; Diago, M.; Craxì, A.; Silva, M.; Bedossa, P.; Mukhopadhyay, P.; Griffel, L.; Burroughs, M.; Brass, C.; Albrecht, J.; Epic Study Group. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009, 136, 1618-1628.
120. Jensen, D.M.; Marcellin, P.; Freilich, B.; Andreone, P.; Di Bisceglie, A.; Brandão-Mello, C.E.; Reddy, K.R.; Craxì, A.; Martin, A.O.; Teuber, G.; Messinger, D.; Thommes, J.A.; Tietz, A. Retreatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann. Intern. Med. 2009, 150, 528-540.
121. Hézode, C.; Forestier, N.; Dusheiko, G.; Ferenci, P.; Pol, S.; Goeser, T.; Bronowicki, J.P.; Bourlière, M.; Gharakhanian, S.; Bengtsson, L.; McNair, L.; George, S.; Kieffer, T.; Kwong, A.; Kauffman, R.S.; Alam, J.; Pawlotsky, J.M.; Zeuzem, S.; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009, 360, 1839-1850.
122. Kwo, P.; Lawitz, E.; McCone, J.; Schiff, E.; Vierling, J.; Pound, D.; Davis, M.; Galati, J.; Gordon, S.; Ravendhran, N.; Rossaro, L.; Anderson, F.; Jacobson, I.; Rubin, R.; Koury, K.; Brass, C.; Chaudhri, E.; Albrecht, J. HCV-SPRINT 1 final results: SVR 24 from a phase II study of Boceprevir plus PegIntron (PegIFN-alfa2b)/Ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C. J. Hepatol. 2009, 50 (Suppl. 1), 4.